VIENNA (Reuters) - An experimental diabetes drug from Bristol-Myers Squibb and AstraZeneca met its main target in a late stage study, achieving significant reductions in glycosylated hemoglobin levels.
When added to the common diabetes pill metformin, dapagliflozin cut both levels of both glycosylated hemoglobin -- an indication of glucose levels -- and fasting plasma glucose in patients with type 2 diabetes after 24 weeks, hitting both its main and secondary targets.
It is the first late stage data on the once-daily pill dapagliflozin, a member of a class of drugs known as SGLT2 inhibitors and designed to block reabsorption of glucose to lower elevated blood sugar levels.
